Guangzheng Eye Hospital Group (002524) Fair Value & Analysis
Industrials · CN · Market cap 1.8B CNY
Fair value as of: Jun 25, 2026
Analysis
Guangzheng Eye Hospital Group (002524) currently trades at ¥3.47, while our model-based Fair Value estimate is ¥0.5600 — implying the stock looks roughly 83.9% overvalued today. We read business quality at 95/100 (high quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Guangzheng Eye Hospital Group Co.,Ltd. provides various ophthalmic medical services in China. It operates through Steel Structure Segment; Energy Segment; and Medical and Health segment. The steel structure segment engaged in steel structure processing and sales and installation business. The energy segment involved in gas station leasing, oil and natural gas sales, and home installation business. The medical and health segment provides ophthalmic medical services. it offers diagnosis and treatment of various eye diseases; medical optometry services; invests in, operates, and manages eye hospitals; and provides related services. In addition, it engages in leasing of houses; and property and consulting services. The company was formerly known as Guangzheng Group Co.,Ltd and changed its name to Guangzheng Eye Hospital Group Co.,Ltd. in October 2020. Guangzheng Eye Hospital Group Co.,Ltd. was founded in 2001 and is headquartered in Xinjiang, China.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Guangzheng Eye Hospital Group (002524) undervalued?
What is the fair value of 002524?
What is the quality score of 002524?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.